Haleon names Vindi Banga Chair; Dave Lewis to step down
Haleon plc announced an orderly Board transition: Sir Dave Lewis will resign as Chair and Director on 31 December 2025, and Vindi Banga will become Chair effective 1 January 2026.
Rhea-AI Filing Summary
Haleon plc announced an orderly Board transition: Sir Dave Lewis will resign as Chair and Director on 31 December 2025, and Vindi Banga will become Chair effective 1 January 2026.
Banga has served as Senior Independent Director since Haleon’s 2022 listing and brings extensive global consumer leadership experience, including 33 years at Unilever and roles at UK Government Investments and GSK. The Board’s decision was unanimous. Remuneration details and a successor for Senior Independent Director will be announced before his appointment takes effect.
Positive
- None.
Negative
- None.
Insights
Orderly chair handover with continuity from an experienced insider.
The announcement sets clear dates: Sir Dave Lewis exits on December 31, 2025, and Vindi Banga assumes the Chair on January 1, 2026. Banga’s current role as Senior Independent Director since the 2022 listing supports continuity in oversight and strategy.
The Board notes a unanimous decision and highlights Banga’s long consumer-sector tenure at Unilever and broader board roles. This suggests a stable transition, with specifics on Chair remuneration and the successor to Senior Independent Director to follow before the effective date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did Haleon (HLN) announce on the 6-K?
Sir Dave Lewis will step down as Chair and Director on 31 December 2025, and Vindi Banga will become Chair effective 1 January 2026.
Who is Vindi Banga and what is his background relevant to Haleon (HLN)?
Banga is Haleon’s Senior Independent Director since 2022 and previously spent 33 years at Unilever, served at UK Government Investments, and was Senior Independent Director at GSK and Marks and Spencer.
Was the appointment of Vindi Banga as Haleon Chair unanimous?
Yes. The Board stated it was unanimous in appointing Vindi Banga as Chair.
When will Haleon disclose Vindi Banga’s Chair remuneration?
Remuneration and the appointment of a successor as Senior Independent Director will be announced in due course and before his appointment takes effect.
Why is Sir Dave Lewis leaving the Haleon Chair role?
He is stepping down to pursue a new executive role, according to his statement.
Does the filing mention any other changes to Haleon’s management team?
It notes that a successor to the Senior Independent Director will be announced before Banga’s appointment becomes effective.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2025
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
10
November 2025 - “Appointment of Vindi Banga as
Chair”
|
99.1
Haleon plc: Appointment of Vindi Banga as Chair
10 November 2025: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces the
resignation of Sir Dave Lewis as Chair and appointment of Vindi
Banga.
Dave Lewis will step down as Chair of the Board and as a Director
of the Company on 31 December 2025 in order to pursue a new
executive role. The Board is pleased to announce the appointment of
Vindi Banga as Chair to succeed Dave with effect from 1 January
2026.
Vindi has served as Senior Independent Director on the Haleon Board
since the Company's listing in 2022. The Board was unanimous in its
appointment of Vindi given his wealth of global corporate and
commercial leadership experience. He has an extensive track record
of delivering outstanding performance in highly competitive global
consumer-focused businesses and a deep understanding of operating
across developed and emerging markets. He spent 33 years at
Unilever plc, where he was also CEO and Chair of Hindustan Unilever
Ltd, one of India's largest listed companies, and was also
responsible for Global Home & Personal Care, Foods and Ice
Cream and a member of the Unilever Executive Board.
Vindi also has extensive international Board experience. He is
currently Chair of UK Government Investments Limited (UKGI) and has
previously served as Senior Independent Director at GSK and Marks
and Spencer plc. Vindi is a partner at CD&R, a leading private
investment firm where he has chaired and served on the boards of
several of the firm's portfolio companies. He is Chair of Council
of Imperial College London.
Vindi's remuneration and the appointment of a successor as Senior
Independent Director will be announced in due course and before
Vindi's appointment as Chair takes effect.
Sir Dave Lewis commented: "After more than three years Haleon is now
well established as an independent listed company. The Board and
Executive team are strong and the business is performing well in a
tough environment. The leverage at demerger has been effectively
addressed, the large overhang managed smoothly and the portfolio
reshaping is progressing.
My decision to step down is a personal one and is related to a new
unique opportunity which I wish to take forward. I would like to
thank my Board colleagues, Brian and his team for their support and
commitment. It has been a privilege to be part of Haleon and I am
confident that the business has a bright future."
Vindi Banga commented: "On
behalf of the Board, I would like to thank Dave for his leadership
and the considerable contribution he has made as Chair of Haleon
since its listing in July 2022. It is a privilege to Chair Haleon
and I look forward to working with the Board and management team to
support Haleon's continued development."
The Company confirms that there is no further information to be
disclosed under the requirements of UKLR 6.4.6R.
Enquiries
|
Investors
|
Media
|
||
|
Jo
Russell
|
+44
7787 392441
|
Zoë Bird
|
+44
7736 746167
|
|
Rakesh
Patel
|
+44
7552 484646
|
Victoria
Durman
|
+44 7894 505730
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
||
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans six major categories - Oral Health,
Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory
Health, Digestive Health and Therapeutic Skin Health and Other. Its
long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne,
Theraflu and Voltaren - are built on trusted science, innovation
and deep human understanding.
For more information, please visit www.haleon.com.
About Vindi Banga
https://www.haleon.com/who-we-are/leadership#manvinder-singh-banga
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
November 10, 2025
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|